Sionna Therapeutics (SION) Net Income towards Common Stockholders (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$26.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 60.75% year-over-year to -$26.8 million; the trailing twelve-month figure through Mar 2026 stood at -$253.8 million (down 113.94% YoY), and the FY2025 full-year result was -$243.7 million, down 113.78% from the prior year.
• Net Income towards Common Stockholders advanced to -$26.8 million in Q1 2026, from -$188.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$8.7 million in Q2 2024 to a low of -$188.4 million in Q4 2025.
• A 3-year average of -$42.7 million and a median of -$20.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 20.61% in 2025, while the deepest fall reached 178.69% in 2025.
• Tracing SION's Net Income towards Common Stockholders over 3 years: stood at -$67.6 million in 2024, then slumped by 178.69% to -$188.4 million in 2025, then surged by 85.79% to -$26.8 million in 2026.
• Business Quant data shows SION's Net Income towards Common Stockholders at -$26.8 million in Q1 2026, -$188.4 million in Q4 2025, and -$20.3 million in Q3 2025.